RARECast: Lessons from Autism on Accelerating Drug Development
August 26, 2016
The genomic revolution promises to unlock the underlying mechanism of many rare diseases and disorders, but progress in translating new discoveries into therapies that benefit patients can be frustratingly slow. We spoke to Robert Ring, former chief scientific officer of Autism Speaks, about innovative efforts he’s been involved with to overcome bottlenecks in translational medicine, advance research, and attract investment into drug development.
Daniel S. Levine is an award-winning business journalist who has reported on the life sciences, economic development, and business policy issues throughout his 25-year career. He founded Levine Media Group in 2013 to provide strategic communications to life sciences companies. He is host of The Bio Report and RARECast podcasts, a senior fellow at the Center for Medicine in the Public Interest, and a member of the advisory board of the California Biotechnology Council.
Do you believe there’s a link?
Learn more about Robert Ring and what he will be speaking about at this year’s 2016 Rare Patient Advocacy Summit by clicking here.
Sign up for updates straight to your inbox.